The pharmacokinetics of etanercept in healthy volunteers

被引:1
|
作者
Korth-Bradley, JM
Rubin, AS
Hanna, RK
Simcoe, DK
Lebsack, ME
机构
[1] Wyeth Ayerst Res, Clin Pharmacokinet, Philadelphia, PA 19101 USA
[2] Immunex Corp, Biometr, Seattle, WA 98101 USA
[3] Immunex Corp, Analyt Resources Dept, Seattle, WA 98101 USA
关键词
phamacokinetics; etanercept;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO describe the pharmacokinetics of etanercept when administered by subcutaneous injection in single doses to healthy volunteers, METHODS: Twenty-six healthy volunteers between 19 and 50 years of age received single doses of etanercept 25 mg by subcutaneous injection into the abdomen. Serial serum samples were collected for 21 days. An enzyme-linked immunosorbent assay with a quantitation limit of 0.3 ng/mL was used to measure the drug concentrations. RESULTS: Etanercept was well tolerated by healthy volunteers. A one-compartment model was found to best describe the concentration-time data and was used to determine the pharmacokinetic parameters. Etanercept is slowly absorbed from the site of injection with a time of peak concentration (+/- SD) of 51 +/- 14 hours; peak concentration was 1.46 +/- 0.72 mg/L. The AUC was 235 +/- 98 mg.h/L, apparent clearance was 132 +/- 85 mL/h, apparent volume of distribution was 12 +/- 6 L, and the half-life was 68 +/- 19 hours. CONCLUSIONS: Etanercept was slowly absorbed and slowly eliminated after subcutaneous administration. Dosing at the recommended rate of 25 mg twice weekly would be expected to result in concentrations of approximately 3 mg/L. Intersubject variability for apparent clearance in healthy volunteers was 64%.
引用
收藏
页码:161 / 164
页数:4
相关论文
共 50 条
  • [11] Pharmacokinetics, Immunogenicity, and Efficacy of Etanercept in Pediatric Patients With Moderate to Severe Plaque Psoriasis
    Langley, Richard G.
    Kasichayanula, Sree
    Trivedi, Mona
    Aras, Girish A.
    Kaliyaperumal, Arunan
    Yuraszeck, Theresa
    Gibbs, John
    Gibbs, Megan
    Kricorian, Greg
    Paller, Amy S.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (03): : 340 - 346
  • [12] Validation of a Test System Based on Enzyme-Linked Immunosorbent Assay for the Evaluation of Etanercept Pharmacokinetics in Patients
    Pisarev, V. V.
    Ivanov, A. V.
    PHARMACEUTICAL CHEMISTRY JOURNAL, 2023, 57 (07) : 1095 - 1098
  • [13] Validation of a Test System Based on Enzyme-Linked Immunosorbent Assay for the Evaluation of Etanercept Pharmacokinetics in Patients
    V. V. Pisarev
    A. V. Ivanov
    Pharmaceutical Chemistry Journal, 2023, 57 : 1095 - 1098
  • [14] Clinical pharmacokinetics of etanercept: A fully humanized soluble recombinant tumor necrosis factor receptor fusion protein
    Zhou, HH
    JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 45 (05): : 490 - 497
  • [15] Unlike tocilizumab, etanercept slightly increases experimental thrombin-induced aggregation in healthy individuals
    Cognasse, Fabrice
    Garraud, Olivier
    Marotte, Hubert
    JOINT BONE SPINE, 2017, 84 (03) : 373 - 375
  • [16] Etanercept
    Alper, Sibel
    TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, 2022, 56 : 33 - 36
  • [17] Etanercept
    Ducharme, Erin
    Weinberg, Jeffrey M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (04) : 491 - 502
  • [18] Pharmacokinetics, efficacy and safety profiles of etanercept monotherapy in Japanese patients with rheumatoid arthritis: review of seven clinical trials
    Takeuchi, Tsutomu
    Miyasaka, Nobuyuki
    Kawai, Shinichi
    Sugiyama, Naonobu
    Yuasa, Hirotoshi
    Yamashita, Noriaki
    Sugiyama, Noriko
    Wagerle, Lorin Craig
    Vlahos, Bonnie
    Wajdulas, Joseph
    MODERN RHEUMATOLOGY, 2015, 25 (02) : 173 - 186
  • [20] Etanercept - A viewpoint
    Khan, MA
    BIODRUGS, 2004, 18 (03) : 206 - 206